Study guide

5.2 Cirrhosis, Portal Hypertension & Hepatic Encephalopathy

CAMC Regional Medical Registration Examination Part 1 MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Registration Framework & Test Strategy

1.1 Exam Format, Administration & Caribbean Medical Registration Pathways 1.2 Clinical Reasoning & Single-Best-Answer MCQ Test-Taking Strategy 1.3 Regional Epidemiology & Caribbean Healthcare Context

2 Chapter 2: Internal Medicine: Cardiovascular Disorders

2.1 Acute Coronary Syndromes & Myocardial Infarction Management 2.2 Heart Failure Syndromes & Cardiogenic Shock 2.3 Cardiac Arrhythmias, Conduction Blocks & BLS/ACLS Algorithms 2.4 Valvular Heart Disease, Infective Endocarditis & Hypertension

3 Chapter 3: Internal Medicine: Respiratory Medicine & Critical Care

3.1 Asthma & Chronic Obstructive Pulmonary Disease Exacerbations 3.2 Community-Acquired Pneumonia, Hospital-Acquired Pneumonia & Tuberculosis 3.3 Pulmonary Embolism, Pleural Effusion & Pneumothorax

4 Chapter 4: Internal Medicine: Endocrinology & Metabolic Disorders

4.1 Diabetes Mellitus, Diabetic Ketoacidosis & Hyperosmolar Hyperglycaemic State 4.2 Thyroid Disorders: Thyrotoxicosis, Hypothyroidism & Thyroid Storm 4.3 Adrenal Disorders, Pituitary Pathology & Calcium Homeostasis

5 Chapter 5: Internal Medicine: Gastroenterology, Hepatology & Nephrology

5.1 Upper & Lower Gastrointestinal Bleeding: Evaluation & Management 5.2 Cirrhosis, Portal Hypertension & Hepatic Encephalopathy 5.3 Acute Kidney Injury & Chronic Kidney Disease Staging 5.4 Fluid, Electrolyte & Acid-Base Emergencies

6 Chapter 6: Internal Medicine: Neurology, Haematology & Infectious Diseases

6.1 Stroke, Transient Ischaemic Attack & Acute Neurological Deficits 6.2 Sickle Cell Disease, Haemoglobinopathies & Transfusion Medicine 6.3 Dengue Fever, Arboviral Infections & Leptospirosis 6.4 HIV/AIDS, Opportunistic Infections & Antimicrobial Stewardship

7 Chapter 7: General Surgery: Acute Abdomen & Surgical Emergencies

7.1 Acute Abdomen: Peritonitis, Appendicitis & Acute Cholecystitis 7.2 Intestinal Obstruction, Bowel Ischaemia & Perforated Viscus 7.3 Abdominal Wall Hernias: Inguinal, Femoral, Umbilical & Strangulation 7.4 Upper & Lower GI Surgical Pathology & Postoperative Complications

8 Chapter 8: General Surgery: Trauma Resuscitation, Shock & Critical Care

8.1 ATLS Primary Survey & Hemorrhagic Shock Resuscitation 8.2 Thoracic Trauma: Tension Pneumothorax, Hemothorax & Flail Chest 8.3 Abdominal & Pelvic Trauma: FAST Examination & Damage Control Surgery 8.4 Traumatic Brain Injury, Burns & Wound Management

9 Chapter 9: General Surgery: Surgical Subspecialties & Perioperative Care

9.1 Urological Emergencies: Acute Retention, Renal Colic, Torsion & Hematuria 9.2 Musculoskeletal Trauma: Fractures, Dislocations & Compartment Syndrome 9.3 Preoperative Assessment, Surgical Site Infections & Fluid Management 9.4 Otolaryngology: Ear, Nose, Throat & Upper Airway Emergencies 9.5 Clinical Ophthalmology: Acute Red Eye, Glaucoma & Retinal Emergencies

10 Chapter 10: Obstetrics: Antenatal Care, Labor & Complications

10.1 Routine Antenatal Care, Screening & Fetal Assessment 10.2 Hypertensive Disorders of Pregnancy: Pre-eclampsia & Eclampsia 10.3 Antepartum Haemorrhage: Placenta Praevia & Placental Abruption 10.4 Normal Labor, Labor Dystocia & Obstetric Analgesia

11 Chapter 11: Obstetrics & Gynaecology: Postpartum & Pathology

11.1 Postpartum Haemorrhage, Normal Puerperium Physiology & Postpartum Care 11.2 Ectopic Pregnancy, Miscarriage & Gestational Trophoblastic Disease 11.3 Abnormal Uterine Bleeding & Pelvic Inflammatory Disease 11.4 Contraception, Cervical Cancer Screening & Gynaecological Malignancies 11.5 Obstetric & Gynaecological Instruments & Cervical Specimen Collection (PAP Smear Procedures)

12 Chapter 12: Paediatric Medicine: Neonatal Care, Growth & Nutrition

12.1 Neonatal Resuscitation, APGAR Scoring & Prematurity Complications 12.2 Neonatal Jaundice: Physiological, Pathological & Kernicterus 12.3 Growth Monitoring, Developmental Milestones & Failure to Thrive 12.4 Protein-Energy Malnutrition: Kwashiorkor, Marasmus & Nutritional Deficiencies

13 Chapter 13: Paediatric Medicine: Common Illnesses & Emergencies

13.1 Acute Gastroenteritis, Dehydration Assessment & WHO ORS Protocols 13.2 Paediatric Respiratory Illness: Croup, Bronchiolitis & Asthma 13.3 Childhood Infections, Exanthems & Caribbean Immunisation Schedules 13.4 Paediatric Surgical & Medical Emergencies: Intussusception & Febrile Seizures 13.5 Social Paediatrics, Child Protection & Vulnerable Child Health

14 Chapter 14: Psychiatry: Clinical Assessment & Psychopharmacology

14.1 Depressive Disorders, Bipolar Affective Disorder & Suicide Risk Assessment 14.2 Psychosis, Schizophrenia & Acute Delirium vs Dementia 14.3 Anxiety Disorders, Substance Misuse & Psychotropic Side Effects

15 Chapter 15: Community Health, Epidemiology & Preventive Medicine

15.1 Epidemiological Study Designs, Measures of Association & Bias 15.2 Screening Test Performance: Sensitivity, Specificity, PPV & NPV 15.3 Outbreak Investigation, Levels of Prevention & Caribbean NCD Control

16 Chapter 16: Internal Medicine: Rheumatology, Connective Tissue & Dermatology

16.1 Connective Tissue & Collagen Vascular Diseases 16.2 Bone & Joint Diseases: Non-Traumatic Arthropathies & Metabolic Bone Disorders 16.3 Clinical Dermatology: Common, Inflammatory, Bullous, Malignant & Drug-Induced Dermatoses

17 Chapter 17: Anaesthetics, Intensive Care & Clinical Measurements

17.1 Important Anaesthetic Techniques, Airway Management & Methods of Administration 17.2 Clinical Measurements & Intensive Care Monitoring: Cardiac Output, Arterial Blood Gases & Pulmonary Functions 17.3 Acute Pain Management, Multimodal Analgesia & Critical Care Sedation

5.2 Cirrhosis, Portal Hypertension & Hepatic Encephalopathy

Key Takeaways Explain This Topic AI

The Serum-Ascites Albumin Gradient (SAAG = Serum Albumin minus Ascitic Albumin) accurately differentiates portal hypertension (SAAG >= 11 g/L or 1.1 g/dL) from non-portal etiologies (SAAG < 11 g/L; e.g., peritoneal carcinomatosis, peritoneal tuberculosis, nephrotic syndrome).

Spontaneous bacterial peritonitis (SBP) is diagnosed by an ascitic fluid absolute neutrophil count (ANC) >= 250 cells/mm3 (0.25 x 10^9/L); start IV antibiotics according to acquisition setting and local resistance (a 3rd-generation cephalosporin for suitable community-acquired cases) plus IV albumin (1.5 g/kg on day 1, 1.0 g/kg on day 3) to prevent hepatorenal syndrome and reduce mortality.

First-line management of cirrhotic ascites comprises dietary sodium restriction (< 2 g/day) and combination diuretics utilizing spironolactone and furosemide titrated in a 100:40 mg ratio; large-volume paracentesis (> 5 L) requires concurrent IV albumin infusion at 8 g per liter of fluid removed.

Hepatic encephalopathy is classified using the West Haven criteria and managed by correcting underlying precipitants (GI bleeding, infection, hypokalemia, constipation, sedatives) alongside non-absorbable disaccharides (lactulose titrated to 2-3 soft stools daily) and add-on rifaximin (550 mg BD).

HRS-AKI occurs in cirrhosis with ascites when AKI persists after adequate volume resuscitation, when indicated, assessed within 24 hours without another primary explanation. A mandatory 48-hour albumin trial is unnecessary; treat established HRS-AKI with terlipressin plus volume-adjusted albumin.

Last updated: November 2026

Pathogenesis & Etiological Spectrum of Cirrhosis

Cirrhosis is the final histological pathway of chronic hepatic parenchymal injury, characterized by diffuse architectural distortion, extensive bridging fibrosis, and the conversion of normal hepatic lobules into structurally abnormal regenerative nodules. In the Caribbean basin, chronic liver disease generates significant inpatient morbidity and premature mortality.

Major Etiological Categories

Chronic Viral Hepatitis: Chronic Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections. HBV remains an important cause in unimmunized populations and migrant communities, with high propensity for direct oncogenesis (hepatocellular carcinoma, HCC) even in the non-cirrhotic phase.

Alcohol-Related Liver Disease (ARLD): Driven by chronic excessive ethanol intake, progressing from steatosis to steatohepatitis, progressive pericellular fibrosis, and micronodular cirrhosis.

Metabolic Dysfunction-Associated Steatohepatitis (MASH, formerly NASH): Strongly linked to the Caribbean epidemic of type 2 diabetes mellitus, metabolic syndrome, and visceral obesity. MASH has rapidly emerged as a leading indication for liver transplantation globally.

Autoimmune & Cholestatic Liver Diseases: Autoimmune hepatitis (characterized by anti-smooth muscle antibodies [ASMA], anti-nuclear antibodies [ANA], and elevated IgG); Primary Biliary Cholangitis (PBC, marked by chronic destruction of interlobular bile ducts, elevated alkaline phosphatase, and positive anti-mitochondrial antibodies [AMA]); and Primary Sclerosing Cholangitis (PSC, characterized by "beaded" stricturing of intra- and extrahepatic bile ducts, strongly associated with ulcerative colitis).

Genetic & Metabolic Infiltrative Disorders: Hereditary hemochromatosis (HFE gene mutations causing parenchymal iron accumulation); Wilson's disease (autosomal recessive ATP7B mutation causing impaired biliary copper excretion, low serum ceruloplasmin, Kayser-Fleischer corneal rings, and basal ganglia copper deposition); and alpha-1 antitrypsin deficiency.

Hemodynamic Pathophysiology of Portal Hypertension

Portal hypertension is defined as a pathological elevation in the hepatic venous pressure gradient (HVPG) above 5 mmHg ; HVPG >=10 mmHg defines clinically significant portal hypertension (CSPH), with an increased risk of decompensation.

Increased Intrahepatic Resistance: Fixed mechanical resistance from collagen deposition in the space of Disse, microvascular thrombosis, and architectural distortion, compounded by dynamic sinusoidal vasoconstriction mediated by activated hepatic stellate cells and deficient endothelial nitric oxide (NO) production.

Splanchnic Vasodilation & Hyperdynamic Circulation: Excessive local release of endogenous endothelial vasodilators (primarily nitric oxide, prostacyclin, and carbon monoxide) induces progressive splanchnic arteriolar vasodilation. Splanchnic blood pooling increases portal venous inflow, maintaining elevated portal pressures despite extensive portosystemic collateral formation.

Effective Circulatory Arterial Volume Depletion: Splanchnic arterial pooling decreases effective arterial blood volume, triggering intense neurohumoral activation of the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system (SNS), and non-osmotic arginine vasopressin (ADH) secretion. This results in profound renal sodium and water retention.

Prognostic Staging: Child-Pugh vs MELD Scores

Objective prognostic models stratify disease severity, guide medical intervention, and direct prioritization for liver transplantation.

Child-Turcotte-Pugh (CTP) Classification

Evaluates five clinical and biochemical parameters, scoring each from 1 to 3 points:

  • Total Bilirubin: < 34 umol/L (1 pt), 34-50 umol/L (2 pts), > 50 umol/L (3 pts)
  • Serum Albumin: > 35 g/L (1 pt), 28-35 g/L (2 pts), < 28 g/L (3 pts)
  • INR / Prothrombin Time: INR < 1.7 (1 pt), 1.7-2.3 (2 pts), > 2.3 (3 pts)
  • Ascites: Absent (1 pt), Mild/diuretic-controlled (2 pts), Moderate/severe/refractory (3 pts)
  • Hepatic Encephalopathy: None (1 pt), Grade 1-2 (2 pts), Grade 3-4 (3 pts)

Child-Pugh Class A (5 to 6 points): Well-compensated cirrhosis; 1-year survival approximately 100%, 2-year survival 85%.

Child-Pugh Class B (7 to 9 points): Significant functional compromise; 1-year survival approximately 80%, 2-year survival 60%.

Child-Pugh Class C (10 to 15 points): Decompensated end-stage cirrhosis; 1-year survival approximately 45%, 2-year survival 35%.

Model for End-Stage Liver Disease (MELD)

An objective logarithmic mathematical model incorporating Bilirubin, INR, Serum Creatinine , and (in MELD-Na) Serum Sodium .

Scores range from 6 to 40; used globally to allocate donor organs for liver transplantation based on 90-day waitlist mortality.

Ascites Evaluation: The Serum-Ascites Albumin Gradient (SAAG)

Ascites is the most common manifestation of decompensated cirrhosis. Diagnostic paracentesis is mandatory for every patient admitted with new-onset ascites or acute clinical deterioration.

Calculating and Interpreting SAAG

The Serum-Ascites Albumin Gradient (SAAG) correlates directly with sinusoidal portal venous hydrostatic pressure:

SAAG Formula: SAAG = Serum Albumin - Ascitic Fluid Albumin (both specimens obtained simultaneously)

High SAAG (>= 11 g/L or >= 1.1 g/dL): Reflects the presence of portal hypertension (transudative process driven by elevated sinusoidal hydrostatic pressures):

Ascitic Fluid Total Protein < 25 g/L: Cirrhosis, late Budd-Chiari syndrome, massive liver metastases.

Ascitic Fluid Total Protein >= 25 g/L: Cardiac ascites (congestive heart failure, constrictive pericarditis), early Budd-Chiari syndrome, sinusoidal obstruction syndrome (hepatic veno-occlusive disease).

Low SAAG (< 11 g/L or < 1.1 g/dL): Excludes portal hypertension (exudative process driven by increased peritoneal capillary permeability or lymphatic obstruction):

  • Peritoneal carcinomatosis (ovarian, gastric, or colonic malignancies)
  • Tuberculous peritonitis
  • Nephrotic syndrome (severe systemic hypoalbuminemia)
  • Pancreatic ascites (pancreatitis or duct disruption, marked by ascitic amylase > 1000 IU/L)
  • Biliary leak / post-surgical ascites
  • Medical Management of Ascites & Large-Volume Paracentesis

Dietary Sodium Restriction: Limit dietary sodium intake to < 2000 mg/day (88 mmol/day) . Strict fluid restriction (< 1.0-1.5 L/day) is not indicated unless serum sodium falls below 125 mmol/L .

Diuretic Therapy: Combination diuretic therapy is significantly more effective than monotherapy:

Initiate Spironolactone 100 mg once daily (aldosterone antagonist) plus Furosemide 40 mg once daily (loop diuretic).

Maintain the 100:40 ratio when titrating doses (up to a maximum of Spironolactone 400 mg and Furosemide 160 mg daily) to achieve a daily weight loss of 0.5 kg (or 1.0 kg if peripheral edema is present) while preserving normokalemia.

Hold or reduce diuretics for AKI, hypovolemia, serum sodium <125 mmol/L, or severe hypokalemia/hyperkalemia; reassess volume status, renal function and electrolytes.

Large-Volume Paracentesis (LVP): First-line therapy for tense, symptomatic, or refractory ascites.

Paracentesis-Induced Circulatory Dysfunction (PICD): Removing large volumes of ascitic fluid triggers rapid splanchnic pooling, further lowering systemic vascular resistance and precipitating acute renal failure and early mortality. When > 5 Liters of ascites is removed , administer intravenous salt-poor albumin at a dose of 8 g per liter of fluid removed (e.g., 40 g of 20% albumin for a 5 L paracentesis, or 64 g for an 8 L paracentesis).

Spontaneous Bacterial Peritonitis (SBP)

Spontaneous bacterial peritonitis is an acute bacterial infection of ascitic fluid without an identifiable surgically treatable intra-abdominal source. It occurs in up to 25% of hospitalized cirrhotic patients with ascites, originating from enteric bacterial translocation across an edematous gut wall.

Clinical Presentation & Diagnostic Criteria

Symptoms can be subtle: fever, chills, diffuse abdominal tenderness, altered mental status, or sudden worsening of renal function. In 10-20% of cases, patients are completely asymptomatic.

Diagnostic Gold Standard: Paracentesis demonstrating an ascitic fluid absolute neutrophil count (ANC) >= 250 cells/mm3 (>= 0.25 x 10^9/L) :

Ascitic ANC Formula: Ascitic ANC = Total WBC count × (% Neutrophils / 100)

Ascitic fluid must be inoculated directly into blood culture bottles at the bedside prior to initiating antibiotics (common isolates: Escherichia coli , Klebsiella pneumoniae , Streptococcus pneumoniae ).

Evidence-Based Treatment Protocol

Empiric Antimicrobial Therapy: For suitable community-acquired SBP, use an IV third-generation cephalosporin (Cefotaxime 2 g every 8 hours or Ceftriaxone 1–2 g daily) for 5–7 days. Healthcare-associated infection, severe sepsis or resistance risk requires broader empirical coverage according to local protocol, then culture-guided treatment.

Intravenous Albumin Infusion: The landmark randomized trial by Sort et al. demonstrated that administering IV albumin reduces the incidence of hepatorenal syndrome from 30% to 10% and reduces hospital mortality from 29% to 10%. Administer 1.5 g/kg IV within 6 hours of diagnosis , followed by 1.0 g/kg IV on day 3 .

Secondary Prophylaxis: Following recovery from SBP, long-term secondary prophylaxis with oral Norfloxacin 400 mg daily or Ciprofloxacin 500 mg daily (or Trimethoprim-sulfamethoxazole) is mandatory to prevent recurrent infection.

Hepatic Encephalopathy (HE)

Hepatic encephalopathy is a spectrum of neuropsychiatric abnormalities seen in advanced liver failure and portosystemic shunting, caused by the failure of the liver to detoxify gut-derived neurotoxins (chiefly ammonia, NH3 ), which cross the blood-brain barrier and induce astrocyte swelling and cerebral edema.

The West Haven Grading System

Grade 1: Subtle behavioral changes, mild confusion, sleep rhythm inversion (insomnia at night, daytime somnolence), shortened attention span. Asterixis is absent.

Grade 2: Obvious lethargy, apathy, disorientation to time/day, inappropriate social behavior, slurred speech. Asterixis (flapping tremor) is easily elicited .

Grade 3: Somnolence to semi-stupor, responsive only to loud voice or shaking, marked confusion, gross disorientation. Asterixis usually present if patient can cooperate.

Grade 4: Frank coma; unresponsive to verbal commands. Decerebrate or decorticate posturing may be seen.

Precipitating Factors

Hepatic encephalopathy is almost invariably provoked by an identifiable secondary insult. Common triggers include:

  • Gastrointestinal bleeding (massive protein load in the gut converted to ammonia)
  • Infections (SBP, urinary tract infection, pneumonia)

Electrolyte disturbances: hypokalemia and metabolic alkalosis (induced by excessive diuretics; alkalosis shifts ionic NH4+ to diffusible NH3, while hypokalemia increases renal ammonia production)

  • Constipation (prolonged colonic transit increases bacterial ammonia generation)
  • Dehydration and acute kidney injury
  • Administration of sedatives, opioids, or benzodiazepines
  • Management Strategy

Identify and Correct Precipitants: Stop sedatives and diuretics, treat infection, manage GI bleeding, and correct hypokalemia.

Lactulose (Non-absorbable synthetic disaccharide): First-line therapy. Colonic bacteria ferment lactulose into lactic and acetic acids, lowering intraluminal pH. Acidification converts lipophilic, diffusible ammonia (NH3) into non-diffusible ammonium (NH4+), trapping it within the bowel lumen for excretion ("ammonia trapping"). It also acts as an osmotic laxative. Administer 20 to 30 g (30 to 45 mL) orally 3-4 times daily, titrated to achieve 2 to 3 soft bowel movements per day .

Rifaximin: A non-absorbable oral rifamycin antibiotic (550 mg orally twice daily) that targets urease-producing gut microflora. Indicated as add-on therapy to lactulose for secondary prevention of recurrent encephalopathy episodes.

Hepatorenal Syndrome (HRS-AKI)

HRS-AKI is a phenotype of acute kidney injury in advanced cirrhosis with ascites, driven by circulatory dysfunction and renal vasoconstriction. Tubular injury, proteinuria or pre-existing CKD may coexist; assess whether another process primarily explains the AKI.

Diagnostic Criteria (ICA-ADQI 2024)

Cirrhosis with ascites.

Creatinine increase at least 26.5 umol/L within 48 hours, at least 50% above baseline within 7 days, and/or urine output <=0.5 mL/kg/hour for at least 6 hours .

No improvement within 24 hours after adequate volume resuscitation, when clinically indicated . Assess volume status promptly; do not require albumin for 48 hours in a euvolemic or overloaded patient.

No strong evidence that another process primarily explains the AKI, such as septic shock requiring vasopressors, drug-induced injury, obstruction or acute glomerular disease.

Review diuretics/nephrotoxins, urine findings and renal imaging. Infection without shock, proteinuria or CKD does not automatically exclude coexisting HRS-AKI.

Medical Management

Vasoconstrictor Therapy + Albumin: Splanchnic vasoconstrictors blunt splanchnic arterial pooling, elevating systemic arterial pressure and improving renal perfusion:

Terlipressin: IV bolus 1 mg every 4 to 6 hours (or continuous infusion up to 2-12 mg/day) plus IV Albumin 20 to 40 g/day , adjusted daily to volume status and withheld for overload or pulmonary edema.

Alternative regimens (if terlipressin unavailable): Norepinephrine continuous infusion plus IV albumin, or oral Midodrine (alpha-1 agonist) plus subcutaneous Octreotide plus IV albumin.

Definitive Cure: Orthotopic liver transplantation remains the definitive cure for HRS.

Differential Matrix: SAAG & Ascitic Fluid Characteristics

  • Clinical Diagnosis SAAG (g/L) Ascitic Total Protein Ascitic Fluid WBC & Features
  • Cirrhosis / Portal HTN >= 11 < 25 g/L Clear/straw, neutrophils (ANC) <250/mm3, low albumin
  • Cardiac Ascites (CHF/Pericarditis) >= 11 >= 25 g/L Elevated total protein due to uninjured sinusoidal barrier

Spontaneous Bacterial Peritonitis >= 11 Variable (often < 10 g/L) Neutrophils (ANC) >=250/mm3 ; culture may be positive or negative

  • Peritoneal Carcinomatosis < 11 >= 25 g/L Bloody or turbid, positive malignant cytology, high LDH
  • Tuberculous Peritonitis < 11 >= 25 g/L High lymphocytes, elevated Adenosine Deaminase (ADA > 30 U/L)
  • Nephrotic Syndrome < 11 < 25 g/L Low total protein due to profound systemic hypoalbuminemia
  • Pancreatic Ascites < 11 >= 25 g/L Marked elevation of ascitic amylase (> 1000 IU/L)

Loading diagram... Clinical Pathway for Cirrhotic Ascites, SBP & Hepatorenal Syndrome